Arovella Therapeutics has named Dr Nicole Van Der Weerden as acting CEO following Dr Michael Baker’s departure, positioning her to steer the company through the critical phase I trial of its CAR-iNKT therapy ALA-101.
- Dr Nicole Van Der Weerden takes over as acting CEO
- Leadership change coincides with upcoming ALA-101 phase I trial
- Van Der Weerden’s salary matches predecessor’s at $386,250 plus super
- Company to update market on permanent CEO search process
- ALA-101 targets CD19-positive blood cancers with allogeneic CAR-iNKT cells
Leadership Shift at a Pivotal Moment
Arovella Therapeutics (ASX:ALA) has swiftly appointed Dr Nicole Van Der Weerden as acting CEO following the resignation and termination of Dr Michael Baker. The timing is critical, with Arovella gearing up for the phase I clinical trial of its lead CAR-iNKT cell therapy candidate, ALA-101. Dr Van Der Weerden, who joined as COO in 2023, steps into the role with a clear mandate to advance the company’s clinical ambitions.
Her appointment comes just days after the company’s earlier leadership shake-up, which included a board overhaul and strategic review, underscoring a period of significant transition for Arovella. The company has committed to updating the market on the search for a permanent CEO, leaving some uncertainty about the long-term leadership trajectory.
Experienced Hands at the Helm
Dr Van Der Weerden brings over 18 years of biotech leadership experience, notably from Hexima Ltd where she held roles including CEO and COO. Her background in advancing drug candidates through preclinical and clinical development aligns closely with Arovella’s upcoming clinical milestones. She holds a PhD in Biochemistry, an MBA from Melbourne Business School, and is a graduate of the Australian Institute of Company Directors.
Her elevation to acting CEO includes a salary adjustment to match Dr Baker’s remuneration of $386,250 plus superannuation, reflecting the company’s recognition of the role’s demands and her qualifications. Chairman David Williams praised her leadership, highlighting her recent strategic engagement at the ISCT 2026 conference in Dublin, which the board attended.
Clinical Trial and Technology Focus
ALA-101, Arovella’s lead product, is an allogeneic CAR-iNKT cell therapy targeting CD19-positive lymphomas and leukaemias. The therapy leverages multiple tumour-recognition mechanisms, including an invariant T cell receptor and NKG2D expression, which may enhance its efficacy against blood cancers. The US FDA has already accepted the Investigational New Drug application, clearing the path for first-in-human trials.
This trial represents a major inflection point for Arovella, as it tests the clinical potential of its technology platform licensed from Imperial College London. The company is also developing ALA-105, a solid tumour candidate armed with cytokine-enhanced CAR-iNKT cells targeting CLDN18.2, reflecting a broader pipeline strategy.
Dr Van Der Weerden’s leadership will be under scrutiny as the company navigates regulatory and operational challenges ahead. The recent FDA IND acceptance and TGA streamlined trial approval underscore the regulatory progress that sets the stage for clinical advancement.
Bottom Line?
Arovella’s leadership change places an experienced biotech executive at the helm during a critical trial launch, but the permanent CEO search and clinical execution will shape the company’s near-term trajectory.
Questions in the middle?
- How will Dr Van Der Weerden balance acting CEO duties with ongoing COO responsibilities?
- What criteria and timeline will Arovella set for appointing a permanent CEO?
- How might leadership changes impact investor confidence as the ALA-101 trial progresses?